和元生物(688238) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥60,498,633.08, a decrease of 14.56% compared to the same period last year[3]. - The total profit for the period was -¥57,359,573.87, with a year-to-date total profit of -¥160,131,214.55[3]. - The net profit attributable to shareholders was -¥57,543,183.53 for the quarter, and -¥162,113,304.23 year-to-date[3]. - For the period from January to September 2025, the company achieved a total revenue of RMB 180.35 million, a decrease of 1.91% compared to the same period last year[13]. - Total operating revenue for the first three quarters of 2025 was CNY 180,353,622.06, a decrease of 1.38% compared to CNY 183,867,467.02 in the same period of 2024[22]. - Net loss for the first three quarters of 2025 was CNY 162,017,387.18, compared to a net loss of CNY 190,249,411.55 in 2024, indicating an improvement of approximately 14.8%[23]. - The company reported a net loss of CNY 137,813,466.84 for the first three quarters of 2025, slightly improved from a loss of CNY 139,868,068.54 in the same period of 2024[32]. - The total comprehensive income for the first three quarters of 2025 was CNY 3,466,939.99, contrasting with a total comprehensive loss of CNY 97,860,871.56 in the previous year[34]. Research and Development - Research and development expenses totaled ¥11,447,822.59, accounting for 18.92% of operating revenue, an increase of 4.70 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were CNY 34,661,199.52, down 11.5% from CNY 39,151,904.55 in 2024[23]. - Research and development expenses for the first three quarters of 2025 were CNY 7,103,505.30, down from CNY 9,531,235.41 in 2024, indicating a reduction of 25.5%[33]. - The company added 1 new invention patent and 6 domestic registered trademarks during the reporting period, with a total of 28 invention patents held[14]. Assets and Liabilities - Total assets at the end of the period were ¥2,116,971,711.57, a decrease of 7.34% from the end of the previous year[4]. - The equity attributable to shareholders decreased by 14.85% to ¥1,481,419,704.38 compared to the end of the previous year[4]. - The company's total assets decreased to CNY 2,116,971,711.57 in 2025 from CNY 2,284,740,741.02 in 2024, reflecting a decline of about 7.35%[20]. - Total liabilities increased to CNY 635,700,803.78 in 2025 from CNY 545,193,225.79 in 2024, representing an increase of approximately 16.58%[20]. - The total current assets as of September 30, 2025, were RMB 536.85 million, compared to RMB 690.43 million at the end of 2024[18]. - The total equity decreased to CNY 1,856,740,517.14 from CNY 1,951,617,896.66, indicating a decline in shareholder value[32]. Cash Flow - The company reported a net cash flow from operating activities of -¥110,580,815.39 year-to-date[3]. - The company's cash flow from operating activities for the first three quarters of 2025 was CNY 184,194,824.98, compared to CNY 166,602,196.16 in 2024, showing an increase of about 10.5%[26]. - The net cash flow from operating activities was CNY -110,580,815.39, showing a slight improvement from CNY -131,849,971.83 in the previous period[28]. - The net cash flow from operating activities for the first three quarters of 2025 was a negative CNY 140,060,624.34, an improvement from a negative CNY 244,030,174.45 in 2024[37]. - The net cash flow from investing activities was CNY -130,674,078.76, an improvement from CNY -232,360,860.25 in the previous period[28]. - Cash inflow from investment activities in the first three quarters of 2025 was CNY 240,358,095.33, compared to CNY 38,781,310.07 in the same period of 2024[37]. Business Operations - The decline in revenue was primarily due to a decrease in income from cell and gene therapy business[8]. - The revenue from cell and gene therapy CRO business was RMB 61.997 million, reflecting a growth of 2.81% year-over-year[13]. - The revenue from cell and gene therapy CDMO business was RMB 96.702 million, down 9.72% year-over-year, primarily due to the types of CDMO orders executed during the reporting period[13]. - Other main businesses, including research reagents and cell storage services, generated revenue of RMB 21.386 million, an increase of 55.99% year-over-year[13]. - The company secured over RMB 120 million in new CDMO orders during the reporting period[14]. - The company assisted clients in obtaining 16 IND application approvals in the US and China, including 1 FDA approval[14]. - As of September 30, 2025, the company had a total of 60 IND application approvals, with 14 from the FDA[14]. - The company's operating profit for the first three quarters of 2025 was CNY 3,144,311.43, a recovery from an operating loss of CNY 95,032,531.01 in the previous year[34]. - The cash outflow for purchasing goods and services in the first three quarters of 2025 was CNY 123,954,890.32, significantly higher than CNY 70,269,169.41 in 2024[37].